2025-09-09 – Press Releases – www.prnewswire.com
MELBOURNE, Australia and INDIANAPOLIS, Sept. 10, 2025 /PRNewswire/ — Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces it has dosed the first patient in a Phase 3 clinical trial aimed at expanding the indications for Illuccix® and Gozellix® (kits for the…
